Bosutinib in the management of chronic myelogenous leukemia
Gunhild Keller-von Amsberg, Philippe SchafhausenDepartment of Hematology and Oncology and, Stem Cell Transplantation and Pulmonology Division, Oncological Center, University Hospital Hamburg-Eppendorf, Hamburg, GermanyAbstract: Bosutinib (SKI-606) is an orally available, once-daily dual Src and Abl...
Guardado en:
Autores principales: | Keller-von Amsberg G, Schafhausen P |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cbaf3b78e7884248a6a18fa561a9eb41 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
por: Emole J, et al.
Publicado: (2016) -
Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
por: Judith E Karp, et al.
Publicado: (2008) -
Dynamics and potential impact of the immune response to chronic myelogenous leukemia.
por: Peter S Kim, et al.
Publicado: (2008) -
Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
por: Harnicar S, et al.
Publicado: (2014) -
Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
por: Maiko Abumiya, et al.
Publicado: (2021)